1
|
Aguilar A, Wang S. Therapeutic Strategies to Activate p53. Pharmaceuticals (Basel) 2022; 16:24. [PMID: 36678521 PMCID: PMC9866379 DOI: 10.3390/ph16010024] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2022] [Revised: 12/13/2022] [Accepted: 12/13/2022] [Indexed: 12/28/2022] Open
Abstract
The p53 protein has appropriately been named the "guardian of the genome". In almost all human cancers, the powerful tumor suppressor function of p53 is compromised by a variety of mechanisms, including mutations with either loss of function or gain of function and inhibition by its negative regulators MDM2 and/or MDMX. We review herein the progress made on different therapeutic strategies for targeting p53.
Collapse
Affiliation(s)
- Angelo Aguilar
- The Rogel Cancer Center, Departments of Internal Medicine, Pharmacology and Medicinal Chemistry, University of Michigan, Ann Arbor, MI 48109, USA
| | - Shaomeng Wang
- The Rogel Cancer Center, Departments of Internal Medicine, Pharmacology and Medicinal Chemistry, University of Michigan, Ann Arbor, MI 48109, USA
| |
Collapse
|
2
|
Huckvale R, Harnden AC, Cheung KMJ, Pierrat OA, Talbot R, Box GM, Henley AT, de Haven Brandon AK, Hallsworth AE, Bright MD, Akpinar HA, Miller DSJ, Tarantino D, Gowan S, Hayes A, Gunnell EA, Brennan A, Davis OA, Johnson LD, de Klerk S, McAndrew C, Le Bihan YV, Meniconi M, Burke R, Kirkin V, van Montfort RLM, Raynaud FI, Rossanese OW, Bellenie BR, Hoelder S. Improved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6 In Vivo. J Med Chem 2022; 65:8191-8207. [PMID: 35653645 PMCID: PMC9234961 DOI: 10.1021/acs.jmedchem.1c02175] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Indexed: 11/30/2022]
Abstract
The transcriptional repressor BCL6 is an oncogenic driver found to be deregulated in lymphoid malignancies. Herein, we report the optimization of our previously reported benzimidazolone molecular glue-type degrader CCT369260 to CCT373566, a highly potent probe suitable for sustained depletion of BCL6 in vivo. We observed a sharp degradation SAR, where subtle structural changes conveyed the ability to induce degradation of BCL6. CCT373566 showed modest in vivo efficacy in a lymphoma xenograft mouse model following oral dosing.
Collapse
Affiliation(s)
- Rosemary Huckvale
- Cancer
Research UK Cancer Therapeutics Unit, The
Institute of Cancer Research, London SM2 5NG, U.K.
| | - Alice C. Harnden
- Cancer
Research UK Cancer Therapeutics Unit, The
Institute of Cancer Research, London SM2 5NG, U.K.
| | - Kwai-Ming J. Cheung
- Cancer
Research UK Cancer Therapeutics Unit, The
Institute of Cancer Research, London SM2 5NG, U.K.
| | - Olivier A. Pierrat
- Cancer
Research UK Cancer Therapeutics Unit, The
Institute of Cancer Research, London SM2 5NG, U.K.
| | - Rachel Talbot
- Cancer
Research UK Cancer Therapeutics Unit, The
Institute of Cancer Research, London SM2 5NG, U.K.
| | - Gary M. Box
- Cancer
Research UK Cancer Therapeutics Unit, The
Institute of Cancer Research, London SM2 5NG, U.K.
| | - Alan T. Henley
- Cancer
Research UK Cancer Therapeutics Unit, The
Institute of Cancer Research, London SM2 5NG, U.K.
| | | | - Albert E. Hallsworth
- Cancer
Research UK Cancer Therapeutics Unit, The
Institute of Cancer Research, London SM2 5NG, U.K.
| | - Michael D. Bright
- Cancer
Research UK Cancer Therapeutics Unit, The
Institute of Cancer Research, London SM2 5NG, U.K.
| | - Hafize Aysin Akpinar
- Cancer
Research UK Cancer Therapeutics Unit, The
Institute of Cancer Research, London SM2 5NG, U.K.
| | - Daniel S. J. Miller
- Cancer
Research UK Cancer Therapeutics Unit, The
Institute of Cancer Research, London SM2 5NG, U.K.
| | - Dalia Tarantino
- Cancer
Research UK Cancer Therapeutics Unit, The
Institute of Cancer Research, London SM2 5NG, U.K.
| | - Sharon Gowan
- Cancer
Research UK Cancer Therapeutics Unit, The
Institute of Cancer Research, London SM2 5NG, U.K.
| | - Angela Hayes
- Cancer
Research UK Cancer Therapeutics Unit, The
Institute of Cancer Research, London SM2 5NG, U.K.
| | - Emma A. Gunnell
- Cancer
Research UK Cancer Therapeutics Unit, The
Institute of Cancer Research, London SM2 5NG, U.K.
- Division
of Structural Biology, The Institute of
Cancer Research, London SM2 5NG, U.K.
| | - Alfie Brennan
- Cancer
Research UK Cancer Therapeutics Unit, The
Institute of Cancer Research, London SM2 5NG, U.K.
| | - Owen A. Davis
- Cancer
Research UK Cancer Therapeutics Unit, The
Institute of Cancer Research, London SM2 5NG, U.K.
| | - Louise D. Johnson
- Cancer
Research UK Cancer Therapeutics Unit, The
Institute of Cancer Research, London SM2 5NG, U.K.
| | - Selby de Klerk
- Cancer
Research UK Cancer Therapeutics Unit, The
Institute of Cancer Research, London SM2 5NG, U.K.
| | - Craig McAndrew
- Cancer
Research UK Cancer Therapeutics Unit, The
Institute of Cancer Research, London SM2 5NG, U.K.
| | - Yann-Vaï Le Bihan
- Cancer
Research UK Cancer Therapeutics Unit, The
Institute of Cancer Research, London SM2 5NG, U.K.
- Division
of Structural Biology, The Institute of
Cancer Research, London SM2 5NG, U.K.
| | - Mirco Meniconi
- Cancer
Research UK Cancer Therapeutics Unit, The
Institute of Cancer Research, London SM2 5NG, U.K.
| | - Rosemary Burke
- Cancer
Research UK Cancer Therapeutics Unit, The
Institute of Cancer Research, London SM2 5NG, U.K.
| | - Vladimir Kirkin
- Cancer
Research UK Cancer Therapeutics Unit, The
Institute of Cancer Research, London SM2 5NG, U.K.
| | - Rob L. M. van Montfort
- Cancer
Research UK Cancer Therapeutics Unit, The
Institute of Cancer Research, London SM2 5NG, U.K.
- Division
of Structural Biology, The Institute of
Cancer Research, London SM2 5NG, U.K.
| | - Florence I. Raynaud
- Cancer
Research UK Cancer Therapeutics Unit, The
Institute of Cancer Research, London SM2 5NG, U.K.
| | - Olivia W. Rossanese
- Cancer
Research UK Cancer Therapeutics Unit, The
Institute of Cancer Research, London SM2 5NG, U.K.
| | - Benjamin R. Bellenie
- Cancer
Research UK Cancer Therapeutics Unit, The
Institute of Cancer Research, London SM2 5NG, U.K.
| | - Swen Hoelder
- Cancer
Research UK Cancer Therapeutics Unit, The
Institute of Cancer Research, London SM2 5NG, U.K.
| |
Collapse
|
3
|
Patrício RPS, Videira PA, Pereira F. A computer-aided drug design approach to discover tumour suppressor p53 protein activators for colorectal cancer therapy. Bioorg Med Chem 2022; 53:116530. [PMID: 34861473 DOI: 10.1016/j.bmc.2021.116530] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2021] [Revised: 11/02/2021] [Accepted: 11/19/2021] [Indexed: 02/03/2023]
Abstract
Colorectal cancer (CRC) is the third most detected cancer and the second foremost cause of cancer deaths in the world. Intervention targeting p53 provides potential therapeutic strategies, but thus far no p53-based therapy has been successfully translated into clinical cancer treatment. Here we developed a Quantitative Structure-Activity Relationships (QSAR) classification models using empirical molecular descriptors and fingerprints to predict the activity against the p53 protein, using the potency value with the active or inactive label, were developed. These models were built using in total 10,505 molecules that were extracted from the ChEMBL, ZINC and Reaxys® databases, and recent literature. Three machine learning (ML) techniques e.g., Random Forest, Support Vector Machine, Convolutional Neural Network were explored to build models for p53 inhibitor prediction. The performances of the models were successfully evaluated by internal and external validation. Moreover, based on the best in silico p53 model, a virtual screening campaign was carried out using 1443 FDA-approved drugs that were extracted from the ZINC database. A list of virtual screening hits was assented on base of some limits established in this approach, such as: (1) probability of being active against p53; (2) applicability domain; (3) prediction of the affinity between the p53, and ligands, through molecular docking. The most promising according to the limits established above was dihydroergocristine. This compound revealed cytotoxic activity against a p53-expressing CRC cell line with an IC50 of 56.8 µM. This study demonstrated that the computer-aided drug design approach can be used to identify previously unknown molecules for targeting p53 protein with anti-cancer activity and thus pave the way for the study of a therapeutic solution for CRC.
Collapse
Affiliation(s)
- Rui P S Patrício
- LAQV and REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Caparica, Portugal; UCIBIO, Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Caparica, Portugal
| | - Paula A Videira
- UCIBIO, Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Caparica, Portugal
| | - Florbela Pereira
- LAQV and REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Caparica, Portugal.
| |
Collapse
|
4
|
Zhang QZ, Li ZY, Zhang L, Lv N, Pan Q, Ke CY, Zhang XL. Synthesis of [(3S,5R)-3-Hydroxy-5-methylpiperidin-1-yl](2-methylpyridin-3-yl)methanone. RUSSIAN JOURNAL OF ORGANIC CHEMISTRY 2021. [DOI: 10.1134/s1070428020120246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
5
|
Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives. Acta Pharm Sin B 2020; 10:1253-1278. [PMID: 32874827 PMCID: PMC7452049 DOI: 10.1016/j.apsb.2020.01.003] [Citation(s) in RCA: 56] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2019] [Revised: 10/31/2019] [Accepted: 12/26/2019] [Indexed: 12/26/2022] Open
Abstract
Blocking the MDM2/X–P53 protein–protein interaction has been widely recognized as an attractive therapeutic strategy for the treatment of cancers. Numerous small-molecule MDM2 inhibitors have been reported since the release of the structure of the MDM2–P53 interaction in 1996, SAR405838, NVP-CGM097, MK-8242, RG7112, RG7388, DS-3032b, and AMG232 currently undergo clinical evaluation for cancer therapy. This review is intended to provide a comprehensive and updated overview of MDM2 inhibitors and proteolysis targeting chimera (PROTAC) degraders with a particular focus on how these inhibitors or degraders are identified from starting points, strategies employed, structure–activity relationship (SAR) studies, binding modes or co-crystal structures, biochemical data, mechanistic studies, and preclinical/clinical studies. Moreover, we briefly discuss the challenges of designing MDM2/X inhibitors for cancer therapy such as dual MDM2/X inhibition, acquired resistance and toxicity of P53 activation as well as future directions.
Collapse
|
6
|
Schnider P, Dolente C, Stalder H, Martin RE, Reinmüller V, Marty R, Wyss Gramberg C, Wagner B, Fischer H, Alker AM, Müller K. Modulation of Pharmacologically Relevant Properties of Piperidine Derivatives by Functional Groups in an Equatorial or Axial β‐Position to the Amino Group. Chembiochem 2019; 21:212-234. [DOI: 10.1002/cbic.201900474] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2019] [Indexed: 11/07/2022]
Affiliation(s)
- Patrick Schnider
- F. Hoffmann-La Roche AGPharmaceutical Research and Early DevelopmentRoche Innovation Center Basel Grenzacherstrasse 124 4070 Basel Switzerland
| | - Cosimo Dolente
- F. Hoffmann-La Roche AGPharmaceutical Research and Early DevelopmentRoche Innovation Center Basel Grenzacherstrasse 124 4070 Basel Switzerland
| | - Henri Stalder
- F. Hoffmann-La Roche AGPharmaceutical Research and Early DevelopmentRoche Innovation Center Basel Grenzacherstrasse 124 4070 Basel Switzerland
- Beim Goldenen Löwen 12 4052 Basel Switzerland
| | - Rainer E. Martin
- F. Hoffmann-La Roche AGPharmaceutical Research and Early DevelopmentRoche Innovation Center Basel Grenzacherstrasse 124 4070 Basel Switzerland
| | - Viktoria Reinmüller
- F. Hoffmann-La Roche AGPharmaceutical Research and Early DevelopmentRoche Innovation Center Basel Grenzacherstrasse 124 4070 Basel Switzerland
- Present address: Auxenion Research AG Gewerbestrasse 18 4123 Allschwil Switzerland
| | - Roman Marty
- F. Hoffmann-La Roche AGPharmaceutical Research and Early DevelopmentRoche Innovation Center Basel Grenzacherstrasse 124 4070 Basel Switzerland
- Present address: Auxenion Research AG Gewerbestrasse 18 4123 Allschwil Switzerland
| | - Caroline Wyss Gramberg
- F. Hoffmann-La Roche AGPharmaceutical Research and Early DevelopmentRoche Innovation Center Basel Grenzacherstrasse 124 4070 Basel Switzerland
| | - Björn Wagner
- F. Hoffmann-La Roche AGPharmaceutical Research and Early DevelopmentRoche Innovation Center Basel Grenzacherstrasse 124 4070 Basel Switzerland
| | - Holger Fischer
- F. Hoffmann-La Roche AGPharmaceutical Research and Early DevelopmentRoche Innovation Center Basel Grenzacherstrasse 124 4070 Basel Switzerland
| | - André M. Alker
- F. Hoffmann-La Roche AGPharmaceutical Research and Early DevelopmentRoche Innovation Center Basel Grenzacherstrasse 124 4070 Basel Switzerland
| | - Klaus Müller
- ETH ZürichLaboratorium für Organische Chemie Vladimir-Prelog-Weg 3 8093 Zürich Switzerland
| |
Collapse
|
7
|
Li G, Kates PA, Dilger AK, Cheng PT, Ewing WR, Groves JT. Manganese-Catalyzed Desaturation of N-Acyl Amines and Ethers. ACS Catal 2019. [DOI: 10.1021/acscatal.9b03457] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- Gang Li
- Department of Chemistry, Princeton University, Princeton, New Jersey 08544, United States
| | - Patrick A. Kates
- Department of Chemistry, Princeton University, Princeton, New Jersey 08544, United States
| | - Andrew K. Dilger
- Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| | - Peter T. Cheng
- Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| | - William R. Ewing
- Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| | - John T. Groves
- Department of Chemistry, Princeton University, Princeton, New Jersey 08544, United States
| |
Collapse
|
8
|
Identification of Kinases Responsible for p53-Dependent Autophagy. iScience 2019; 15:109-118. [PMID: 31048145 PMCID: PMC6495467 DOI: 10.1016/j.isci.2019.04.023] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2018] [Revised: 01/11/2019] [Accepted: 04/17/2019] [Indexed: 01/03/2023] Open
Abstract
In cancer, autophagy is upregulated to promote cell survival and tumor growth during times of nutrient stress and can confer resistance to drug treatments. Several major signaling networks control autophagy induction, including the p53 tumor suppressor pathway. In response to DNA damage and other cellular stresses, p53 is stabilized and activated, while HDM2 binds to and ubiquitinates p53 for proteasome degradation. Thus blocking the HDM2-p53 interaction is a promising therapeutic strategy in cancer; however, the potential survival advantage conferred by autophagy induction may limit therapeutic efficacy. In this study, we leveraged an HDM2 inhibitor to identify kinases required for p53-dependent autophagy. Interestingly, we discovered that p53-dependent autophagy requires several kinases, including the myotonic dystrophy protein kinase-like alpha (MRCKα). MRCKα is a CDC42 effector reported to activate actin-myosin cytoskeletal reorganization. Overall, this study provides evidence linking MRCKα to autophagy and reveals additional insights into the role of kinases in p53-dependent autophagy. HDM2 inhibitors stabilize and activate p53 leading to robust autophagy induction RNAi screen uncovers kinases involved in p53-dependent autophagy ULK1 and the actin cytoskeleton kinase MRCKα mediate p53-induced autophagy
Collapse
|
9
|
Lemos A, Leão M, Soares J, Palmeira A, Pinto M, Saraiva L, Sousa ME. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction. Med Res Rev 2016; 36:789-844. [PMID: 27302609 DOI: 10.1002/med.21393] [Citation(s) in RCA: 62] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2015] [Revised: 02/16/2016] [Accepted: 03/21/2016] [Indexed: 12/12/2022]
Abstract
The growth inhibitory activity of p53 tumor suppressor is tightly regulated by interaction with two negative regulatory proteins, murine double minute 2 (MDM2) and X (MDMX), which are overexpressed in about half of all human tumors. The elucidation of crystallographic structures of MDM2/MDMX complexes with p53 has been pivotal for the identification of several classes of inhibitors of the p53-MDM2/MDMX interaction. The present review provides in silico strategies and screening approaches used in drug discovery as well as an overview of the most relevant classes of small-molecule inhibitors of the p53-MDM2/MDMX interaction, their progress in pipeline, and highlights particularities of each class of inhibitors. Most of the progress made with high-throughput screening has led to the development of inhibitors belonging to the cis-imidazoline, piperidinone, and spiro-oxindole series. However, novel potent and selective classes of inhibitors of the p53-MDM2 interaction with promising antitumor activity are emerging. Even with the discovery of the 3D structure of complex p53-MDMX, only two small molecules were reported as selective p53-MDMX antagonists, WK298 and SJ-172550. Dual inhibition of the p53-MDM2/MDMX interaction has shown to be an alternative approach since it results in full activation of the p53-dependent pathway. The knowledge of structural requirements crucial to the development of small-molecule inhibitors of the p53-MDMs interactions has enabled the identification of novel antitumor agents with improved in vivo efficacy.
Collapse
Affiliation(s)
- Agostinho Lemos
- Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313, Porto, Portugal
| | - Mariana Leão
- UCIBIO/REQUIMTE, Laboratory of Microbiology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313, Porto, Portugal
| | - Joana Soares
- UCIBIO/REQUIMTE, Laboratory of Microbiology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313, Porto, Portugal
| | - Andreia Palmeira
- Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313, Porto, Portugal
| | - Madalena Pinto
- Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313, Porto, Portugal.,CIIMAR-Interdisciplinary Centre of Marine and Environmental Research, University of Porto, Rua de Bragas, 289, 4050-123, Porto, Portugal
| | - Lucília Saraiva
- UCIBIO/REQUIMTE, Laboratory of Microbiology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313, Porto, Portugal
| | - Maria Emília Sousa
- Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313, Porto, Portugal.,CIIMAR-Interdisciplinary Centre of Marine and Environmental Research, University of Porto, Rua de Bragas, 289, 4050-123, Porto, Portugal
| |
Collapse
|
10
|
Chemical Variations on the p53 Reactivation Theme. Pharmaceuticals (Basel) 2016; 9:ph9020025. [PMID: 27187415 PMCID: PMC4932543 DOI: 10.3390/ph9020025] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2016] [Revised: 05/06/2016] [Accepted: 05/09/2016] [Indexed: 01/31/2023] Open
Abstract
Among the tumor suppressor genes, p53 is one of the most studied. It is widely regarded as the "guardian of the genome", playing a major role in carcinogenesis. In fact, direct inactivation of the TP53 gene occurs in more than 50% of malignancies, and in tumors that retain wild-type p53 status, its function is usually inactivated by overexpression of negative regulators (e.g., MDM2 and MDMX). Hence, restoring p53 function in cancer cells represents a valuable anticancer approach. In this review, we will present an updated overview of the most relevant small molecules developed to restore p53 function in cancer cells through inhibition of the p53-MDMs interaction, or direct targeting of wild-type p53 or mutated p53. In addition, optimization approaches used for the development of small molecules that have entered clinical trials will be presented.
Collapse
|
11
|
Bogen SL, Pan W, Gibeau CR, Lahue BR, Ma Y, Nair LG, Seigel E, Shipps GW, Tian Y, Wang Y, Lin Y, Liu M, Liu S, Mirza A, Wang X, Lipari P, Seidel-Dugan C, Hicklin DJ, Bishop WR, Rindgen D, Nomeir A, Prosise W, Reichert P, Scapin G, Strickland C, Doll RJ. Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors. ACS Med Chem Lett 2016; 7:324-9. [PMID: 26985323 DOI: 10.1021/acsmedchemlett.5b00472] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2015] [Accepted: 01/20/2016] [Indexed: 01/02/2023] Open
Abstract
A new subseries of substituted piperidines as p53-HDM2 inhibitors exemplified by 21 has been developed from the initial lead 1. Research focused on optimization of a crucial HDM2 Trp23-ligand interaction led to the identification of 2-(trifluoromethyl)thiophene as the preferred moiety. Further investigation of the Leu26 pocket resulted in potent, novel substituted piperidine inhibitors of the HDM2-p53 interaction that demonstrated tumor regression in several human cancer xenograft models in mice. The structure of HDM2 in complex with inhibitors 3, 10, and 21 is described.
Collapse
Affiliation(s)
- Stéphane L. Bogen
- Discovery
Chemistry, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Weidong Pan
- Discovery
Chemistry, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Craig R. Gibeau
- Discovery
Chemistry, Merck Research Laboratories, Boston, Massachusetts 02115, United States
| | - Brian R. Lahue
- Discovery
Chemistry, Merck Research Laboratories, Boston, Massachusetts 02115, United States
| | - Yao Ma
- Discovery
Chemistry, Merck Research Laboratories, Boston, Massachusetts 02115, United States
| | - Latha G. Nair
- Discovery
Chemistry, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Elise Seigel
- Discovery
Chemistry, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Gerald W. Shipps
- Discovery
Chemistry, Merck Research Laboratories, Boston, Massachusetts 02115, United States
| | - Yuan Tian
- Discovery
Chemistry, Merck Research Laboratories, Boston, Massachusetts 02115, United States
| | - Yaolin Wang
- Discovery
Biology, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Yinghui Lin
- Discovery
Biology, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Ming Liu
- Discovery
Biology, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Suxing Liu
- Discovery
Biology, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Asra Mirza
- Discovery
Biology, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Xiaoying Wang
- Discovery
Biology, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Philip Lipari
- Discovery
Biology, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Cynthia Seidel-Dugan
- Discovery
Biology, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Daniel J. Hicklin
- Discovery
Biology, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - W. Robert Bishop
- Discovery
Biology, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Diane Rindgen
- Pharmacokinetic,
Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Amin Nomeir
- Pharmacokinetic,
Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Winifred Prosise
- Structural
Chemistry, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Paul Reichert
- Structural
Chemistry, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Giovanna Scapin
- Structural
Chemistry, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Corey Strickland
- Structural
Chemistry, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| | - Ronald J. Doll
- Discovery
Chemistry, Merck Research Laboratories, Kenilworth, New Jersey 07033, United States
| |
Collapse
|
12
|
Computational identification of novel piperidine derivatives as potential HDM2 inhibitors designed by fragment-based QSAR, molecular docking and molecular dynamics simulations. Struct Chem 2015. [DOI: 10.1007/s11224-015-0697-2] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|
13
|
Zhao Y, Aguilar A, Bernard D, Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment. J Med Chem 2014; 58:1038-52. [PMID: 25396320 PMCID: PMC4329994 DOI: 10.1021/jm501092z] [Citation(s) in RCA: 337] [Impact Index Per Article: 33.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
![]()
Design of small-molecule inhibitors
(MDM2 inhibitors) to block
the MDM2–p53 protein–protein interaction has been pursued
as a new cancer therapeutic strategy. In recent years, potent, selective,
and efficacious MDM2 inhibitors have been successfully obtained and
seven such compounds have been advanced into early phase clinical
trials for the treatment of human cancers. Here, we review the design,
synthesis, properties, preclinical, and clinical studies of these
clinical-stage MDM2 inhibitors.
Collapse
Affiliation(s)
- Yujun Zhao
- University of Michigan Comprehensive Cancer Center and Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States
| | | | | | | |
Collapse
|